01 Nov MetaLinear
MetaLinear Ltd exploits proteome engineering to uncover, characterise and validate new targets for antibiotics. Their approach, using engineered Affinity Proteins (eAPs), not only aids the identification and characterisation of new targets but provides multiple short-cuts in the traditional target and drug discovery process. Prior to MetaLinear, the founder, Paul Ko Ferrigno, pioneered the development of Affimir™ Technology that now is leveraged via Avacta Group Plc.
BioCity invested in Metalinear because we believe the next generation of antibacterials will come from novel target identification and targeting this at the proteome level offers real differentiation.